How are CYP2C19 and blood sugar related?

CYP2C19 is a drug-metabolizing enzyme, primarily known for processing medications like proton pump inhibitors (e.g., omeprazole) and certain antidepressants. A direct, clinically meaningful link between CYP2C19 variants and blood sugar levels is not supported by strong human evidence. Indirect connections are possible: for instance, long-term use of proton pump inhibitors can alter the gut microbiome, which may influence glucose metabolism. Additionally, CYP2C19 is involved in metabolizing endogenous compounds like melatonin, which has minor effects on blood sugar. However, these effects are small and inconsistent. Most available data come from pharmacokinetic studies or mechanistic hypotheses, not from robust trials showing that CYP2C19 genotype predicts glycemic outcomes. Therefore, current evidence is best described as unclear or mechanistic. Consumer DNA tests reporting CYP2C19 status should not be used to make dietary or lifestyle changes aimed at blood sugar control.